Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Signal transduction inhibitor].
Ueda Y, Saijo N. Ueda Y, et al. Gan To Kagaku Ryoho. 2001 May;28(5):591-600. Gan To Kagaku Ryoho. 2001. PMID: 11383206 Review. Japanese.
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitoh H, Ohe Y, Kodama T, Shimizu M, Nishio K, Ishizuka N, Saijo N. Yamamoto N, et al. Among authors: ueda y. J Clin Oncol. 2005 Feb 20;23(6):1061-9. doi: 10.1200/JCO.2005.11.036. Epub 2005 Jan 18. J Clin Oncol. 2005. PMID: 15657405 Clinical Trial.
Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y. Yamada Y, et al. Among authors: ueda y. Cancer Chemother Pharmacol. 2006 Aug;58(2):173-82. doi: 10.1007/s00280-005-0149-6. Epub 2005 Nov 25. Cancer Chemother Pharmacol. 2006. PMID: 16308697 Clinical Trial.
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.
Murakami H, Ueda Y, Shimoyama T, Yamamoto N, Yamada Y, Arioka H, Tamura T. Murakami H, et al. Among authors: ueda y. Cancer Chemother Pharmacol. 2011 May;67(5):1119-28. doi: 10.1007/s00280-010-1405-y. Epub 2010 Jul 31. Cancer Chemother Pharmacol. 2011. PMID: 20676674 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
Ueda Y, Shimoyama T, Murakami H, Yamamoto N, Yamada Y, Arioka H, Tamura T. Ueda Y, et al. Cancer Chemother Pharmacol. 2011 May;67(5):1101-9. doi: 10.1007/s00280-010-1404-z. Epub 2010 Jul 30. Cancer Chemother Pharmacol. 2011. PMID: 20676675 Free PMC article. Clinical Trial.
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.
Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K. Ninomiya T, et al. Among authors: ueda y. Clin Lung Cancer. 2019 Mar;20(2):134-138. doi: 10.1016/j.cllc.2018.10.008. Epub 2018 Nov 1. Clin Lung Cancer. 2019. PMID: 30514667
4,757 results